Problem
Colorectal cancer is the second leading cause of cancer related
death. Up to 28% of polyps are missed during colonoscopy procedures
due to human factors, allowing polyps to develop into
life-threatening late-stage cancers.
Solution
Ameretat is developing a real-time artificial intelligence, AI,
system that analyzes colonoscopy video streams to highlight and
characterize potential polyps. Our key differentiators:
-
High
sensitivity, including flat lesions.
-
Real-time
performance with minimal disruption.
-
Seamless
integration into existing hospital infrastructure via cloud-based
software, requiring minimal workflow changes.
Impact
Clinical Impact
Reduces polyp miss rate during colonoscopy, enabling earlier,
more effective treatment.
Societal Relevance
A potential 10% improvement in polyp detection could save over
55,000 lives per year and reduce healthcare costs by more than
$2.5 billion annually.
Market Access
Payers
By forming strategic partnerships with health tech providers,
hospitals and screening centers will pay them directly, while we
earn based on licensing agreements with partners.
Users
Gastroenterologists in hospitals and screening centers.
Differentiation
Unlike hardware solutions, our software-driven model avoids high
upfront costs and enables a pay-per-procedure approach, making
adoption easier and more scalable.
Traction
AI model
Developed over four years during a PhD to handle all image types
and any device resolutions, performing exceptionally well even
on very small datasets.
Clinical Data
Built on 14,000+ annotated polyp images from UMCG, in close
collaboration with top clinicians.
Business Foundation
Over 1 year of entrepreneurial training via VentureLab, Life
Cooperative, and continuing with NOM program, with multiple
startup pitch competition wins.
Market
Global market Size of Colorectal cancer diagnostics expected to grow
from $1.3B to $30.2B (2022-2032) at 8.8% CAGR.
AI in Healthcare market valued at $19.27B with 38.5% CAGR projected
through (2022-2030).